The estimated Net Worth of Jeffrey S. Heier is at least $426 Tausend dollars as of 12 May 2022. Jeffrey Heier owns over 15,000 units of Ocular Therapeutix Inc stock worth over $329,160 and over the last 9 years he sold OCUL stock worth over $0. In addition, he makes $96,441 as Independent Director at Ocular Therapeutix Inc.
Jeffrey has made over 2 trades of the Ocular Therapeutix Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he bought 15,000 units of OCUL stock worth $45,750 on 12 May 2022.
The largest trade he's ever made was buying 24,000 units of Ocular Therapeutix Inc stock on 15 March 2019 worth over $99,600. On average, Jeffrey trades about 3,000 units every 89 days since 2015. As of 12 May 2022 he still owns at least 39,000 units of Ocular Therapeutix Inc stock.
You can see the complete history of Jeffrey Heier stock trades at the bottom of the page.
Dr. Jeffrey S. Heier M.D. serves as Independent Director of the Company. Dr. Heier has worked as a vitreoretinal specialist at Ophthalmic Consultants of Boston, or OCB, a large multi-specialty ophthalmology practice with several offices in the Boston, Massachusetts area. He has served as the Director of Vitreoretinal Service of OCB since 2009 and the Director of Retina Research at OCB since 2011, and in 2016 he was appointed Co-President and Medical Director. He has been a partner of the Boston Eye Surgery and Laser Center, the Cape Cod Eye Surgery and Laser Center, and the Plymouth Eye Surgery and Laser Center. Dr. Heier is an advisor or consultant to several biopharmaceutical and medical device companies. Dr. Heier also serves in leadership roles of several professional organizations including as Former President of the New England Ophthalmological Society, as Vice President of the Retinal Society, and as an executive board member of the American Society of Retina Specialists. Dr. Heier holds a B.S. in Biochemistry from Brandeis University and an M.D. from the Boston University School of Medicine. Heier is qualified to serve on our board of directors because of his background in ophthalmology, with an emphasis on back-of-the-eye conditions and diseases, which gives him a perspective that is helpful to the board for understanding our product market.
As the Independent Director of Ocular Therapeutix Inc, the total compensation of Jeffrey Heier at Ocular Therapeutix Inc is $96,441. There are 13 executives at Ocular Therapeutix Inc getting paid more, with Antony Mattessich having the highest compensation of $2,126,150.
Jeffrey Heier is 59, he's been the Independent Director of Ocular Therapeutix Inc since 2015. There are 7 older and 8 younger executives at Ocular Therapeutix Inc. The oldest executive at Ocular Therapeutix Inc is Richard Lindstrom, 72, who is the Independent Director.
Jeffrey's mailing address filed with the SEC is C/O OCULAR THERAPEUTIX, INC., 24 CROSBY DRIVE, BEDFORD, MA, 01730.
Over the last 10 years, insiders at Ocular Therapeutix Inc have traded over $73,512,800 worth of Ocular Therapeutix Inc stock and bought 6,361,550 units worth $38,632,070 . The most active insiders traders include Management Inc. Opaleye, Road Llc Summer und Venture Management Co. V, L.... On average, Ocular Therapeutix Inc executives and independent directors trade stock every 43 days with the average trade being worth of $999,228. The most recent stock trade was executed by Sanjay Nayak on 23 August 2024, trading 1,832 units of OCUL stock currently worth $16,525.
ocular therapeutix, inc. is a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel-based formulation technology. ocular therapeutix’s lead product candidate, dextenza™ (dexamethasone insert) 0.4 mg for intracanalicular use, has completed phase 3 clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery. otx-tp (travoprost insert) is in phase 3 clinical development for the reduction of intraocular pressure in patients with glaucoma and ocular hypertension. the company’s earlier stage assets include otx-tic, a sustained release travoprost intracameral injection for the reduction in intraocular pressure in patients with glaucoma and ocular hypertension, as well as sustained release intravitreal injections for the treatment of retinal diseases. these injections include the development of otx-tki, a tyrosine kinase inhib
Ocular Therapeutix Inc executives and other stock owners filed with the SEC include: